2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2942 Reproductive aging in women with sickle cell disease: Biomarker evidence of an emerging survivorship phenotype

Marwah Farooqui, DO, Xu Zhang, PhD2, Santosh L Saraf, MD3
1 University of Illinois Chicago, Chicago, Illinois, United States
2 University of Illinois Chicago, Chicago, Illinois, United States
3 University of Illinois Chicago, Chicago, Illinois, United States

Background:

Advances in sickle cell disease (SCD) care have improved survival, resulting in a growing population of women reaching midlife and experiencing menopause. However, the impact of SCD on reproductive aging remains unclear. Menopause-related symptoms, including vasomotor symptoms (hot flashes), sleep disturbance, mood changes, and musculoskeletal complaints, overlap with SCD manifestations and may complicate recognition and management. Biomarkers of ovarian reserve may provide insight into reproductive aging trajectories in women with SCD.

Objectives:

To characterize menopause-related symptom burden and reproductive aging biomarkers in women with SCD and evaluate associations between ovarian reserve markers and SCD-related clinical characteristics.

Methods:

Adult women aged ≥30 years with SCD were enrolled in a single-center cross-sectional study. Participants completed an adapted Menopause Quick 6 (MQ6) questionnaire assessing menopause-related symptoms, symptom attribution, and perceived impact of SCD. Clinical characteristics, disease-modifying therapies, laboratory markers, and healthcare utilization were abstracted from the electronic medical record.

A subset of participants (n=36) underwent biomarker analysis from archived biospecimens collected through a pilot translational research study. Serum/plasma samples were analyzed for anti-Müllerian hormone (AMH), inhibin B, and insulin-like growth factor-1 (IGF-1). Associations between biomarkers, menopause symptom burden, reproductive status, and SCD-related clinical characteristics were evaluated using correlation and multivariable regression analyses.

Results:

Among 101 women with SCD, median age was 43 (IQR 36 – 51) years. Menopause-related symptoms were common across reproductive stages and frequently overlapped with SCD manifestations. Among the biomarker subset (n=36; median age 45 (37 – 51) years), mean total MQ6 score was 2.5+/- 1.6, with hot flashes and sleep disturbance among the most frequently reported symptoms.

AMH levels demonstrated marked reduction within the cohort, with a median AMH of 0.06 (0.03 – 0.19) ng/mL. Thirty-four of 36 participants (94%) had AMH levels <1.0 ng/mL, a clinically recognized threshold for diminished ovarian reserve, and 16 of 36 (44%) had AMH levels below the assay detection limit, suggesting a high prevalence of markedly reduced ovarian reserve biomarkers among women with SCD.

Menopause symptom burden was not significantly associated with AMH (Spearman ρ=0.25, p=0.146), inhibin B (ρ=-0.13, p=0.465), or IGF-1 (ρ=-0.07, p=0.697), possibly suggesting that menopause-related symptoms in SCD are multifactorial and not explained solely by ovarian reserve biomarkers.

In multivariable modeling of log-transformed AMH levels increasing age was associated with lower AMH levels as expected (β=-0.33, p<0.001). Importantly, ED admissions were independently associated with lower AMH levels (β=-0.59, p=0.001), suggesting a relationship between greater SCD-related morbidity and reduced ovarian reserve. Interestingly, lower hemoglobin concentration, a biomarker of SCD severity, was associated with lower AMH levels (β=0.35, p=0.003).

Conclusions:

Women with SCD demonstrate substantial menopause-related symptom burden and a high prevalence of markedly reduced ovarian reserve biomarkers. Lower AMH levels were associated with greater healthcare utilization, suggesting that reproductive aging may represent an underrecognized component of SCD morbidity. Menopause-related symptoms were not fully explained by ovarian reserve biomarkers, highlighting the complex interaction between SCD manifestations and reproductive aging. Longitudinal studies are needed to define reproductive aging trajectories and determine whether biomarkers can identify women at risk for early reproductive aging and menopause-related complications.

 

Marwah Farooqui, DO: No relevant conflicts of interest to declare.